Vinod et al. [34] demonstrated, on HER2 overexpressing SKBR3 breast cancer cells, that resveratrol had the ability to cancel docetaxel-associated HER2 phosphorylation, along with further activation of its related-downstream (MAPK and Akt) signaling cascades, at a concentration of 10–25 μM resveratrol and 0.1–10 nM docetaxel. The gene discussed is ERBB2; the disease is breast cancer.